Biomea Fusion shares fell 19.12% to $1.37 on Wednesday after the clinical-stage diabetes and obesity medicines company terminated its proposed public offering. The financing plan, initially announced as an underwritten sale of common stock and pre-funded warrants, had no disclosed size or terms; Biomea had also planned to give the underwriter a 30-day option to buy up to 15% of the securities offered. In a Tuesday SEC filing, the company said topline results from its ongoing Phase I GLP-131 trial of BMF-650 in obese, otherwise healthy volunteers are now expected in October 2026, later than the previously indicated third quarter. Biomea added a cohort in June to test a one-step titration of 200 milligrams once daily for one week followed by 400 milligrams once daily for three weeks and to further optimize weight reduction. The shares remain above their 50-, 100- and 200-day simple moving averages but are below the 20-day average, while an RSI of 45.63 indicates neutral-to-soft momentum. The company’s market capitalization was approximately $123.22 million, and its shares had traded between $0.87 and $2.99 over the prior 52 weeks.